WO2001012168A3 - Produit pharmaceutique utilise ans le traitement d'infections virales, notamment des infections dues au virus de l'immunodeficience humaine (vih) - Google Patents

Produit pharmaceutique utilise ans le traitement d'infections virales, notamment des infections dues au virus de l'immunodeficience humaine (vih) Download PDF

Info

Publication number
WO2001012168A3
WO2001012168A3 PCT/NL2000/000559 NL0000559W WO0112168A3 WO 2001012168 A3 WO2001012168 A3 WO 2001012168A3 NL 0000559 W NL0000559 W NL 0000559W WO 0112168 A3 WO0112168 A3 WO 0112168A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical compositions
iron chelators
compositions containing
containing iron
antiviral pharmaceutical
Prior art date
Application number
PCT/NL2000/000559
Other languages
English (en)
Other versions
WO2001012168A2 (fr
Inventor
Asbeck Bernt Sweder Van
Johannes Josephus Maria Marx
Original Assignee
Faculteit Geneeskunde Universi
Asbeck Bernt Sweder Van
Johannes Josephus Maria Marx
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faculteit Geneeskunde Universi, Asbeck Bernt Sweder Van, Johannes Josephus Maria Marx filed Critical Faculteit Geneeskunde Universi
Priority to AT00952070T priority Critical patent/ATE282430T1/de
Priority to EP00952070A priority patent/EP1257261B1/fr
Priority to AU64831/00A priority patent/AU6483100A/en
Priority to DE60016044T priority patent/DE60016044D1/de
Publication of WO2001012168A2 publication Critical patent/WO2001012168A2/fr
Publication of WO2001012168A3 publication Critical patent/WO2001012168A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents

Abstract

L'invention porte sur un produit pharmaceutique utilisé dans le traitement d'infections virales, notamment d'infections dues au virus de l'immunodéficience humaine (VIH). Selon cette invention, le produit pharmaceutique comprend un composé contenant comme composant actif un chélateur de fer. Des chélateurs de fer appropriés sont sélectionnés dans le groupe d'hydroxamates (tels que défériprone), dans la famille des hydroxypyridinones (telles que défériprone) et dans les produits chimiothérapeutiques se liant à l'acide nucléique (tels que la bléomycine). Un effet synergique est obtenu in vitro lorsqu'en plus du composant contenant le chélateur de fer, on utilise un produit qui contient un autre composé inhibant le virus. L'invention porte également sur un inhibiteur de protéase, de préférence ritonavir, utilisé comme agent antiviral, et sur un autre agent antiviral approprié qui est un inhibiteur de transcriptase inverse, de préférence une didésoxyinosine.
PCT/NL2000/000559 1999-08-13 2000-08-09 Produit pharmaceutique utilise ans le traitement d'infections virales, notamment des infections dues au virus de l'immunodeficience humaine (vih) WO2001012168A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AT00952070T ATE282430T1 (de) 1999-08-13 2000-08-09 Eisenchelator enthaltende antivirale pharmazeutische zusammensetzungen
EP00952070A EP1257261B1 (fr) 1999-08-13 2000-08-09 Compositions pharmaceutiques antivirales contentant un chelateur de fer
AU64831/00A AU6483100A (en) 1999-08-13 2000-08-09 Pharmaceutical product for the treatment of viral infections, in particular of the human immunodeficiency virus (hiv)
DE60016044T DE60016044D1 (de) 1999-08-13 2000-08-09 Eisenchelator enthaltende antivirale pharmazeutische zusammensetzungen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL1012825A NL1012825C2 (nl) 1999-08-13 1999-08-13 Farmaceuticum voor de behandeling van virale infecties in het bijzonder van het humane immunodeficiency virus (HIV).
NL1012825 1999-08-13

Publications (2)

Publication Number Publication Date
WO2001012168A2 WO2001012168A2 (fr) 2001-02-22
WO2001012168A3 true WO2001012168A3 (fr) 2002-06-06

Family

ID=19769735

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2000/000559 WO2001012168A2 (fr) 1999-08-13 2000-08-09 Produit pharmaceutique utilise ans le traitement d'infections virales, notamment des infections dues au virus de l'immunodeficience humaine (vih)

Country Status (6)

Country Link
EP (1) EP1257261B1 (fr)
AT (1) ATE282430T1 (fr)
AU (1) AU6483100A (fr)
DE (1) DE60016044D1 (fr)
NL (1) NL1012825C2 (fr)
WO (1) WO2001012168A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003065991A2 (fr) 2002-02-05 2003-08-14 Bristol-Myers Squibb Company N-substitute3-hydroxy-4-pyridinones et compositions pharmaceutiques contenant ces derniers
EP1694325A4 (fr) * 2003-12-03 2009-03-25 Univ New Jersey Med Procede pour empecher la survie des cellules retrovirales et la formation des retrovirus infectieux
WO2016102541A1 (fr) * 2014-12-22 2016-06-30 Université Libre de Bruxelles Composition comprenant de la vancomycine et de l'orlistat

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015329A1 (fr) * 1991-02-28 1992-09-17 The United States Of America, Represented By The Secretary, United States Department Of Commerce Procedes et compositions pharmaceutiques servant a inhiber la protease du virus de l'immunodeficience humaine
WO1992016200A1 (fr) * 1991-03-20 1992-10-01 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Utilisation de derives d'acide hydroxamique pour l'inhibition de la replication virale

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99843A0 (en) * 1990-11-01 1992-08-18 Merck & Co Inc Synergistic combination of hiv reverse transcriptase inhibitors
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5521161A (en) * 1993-12-20 1996-05-28 Compagnie De Developpment Aguettant S.A. Method of treating HIV in humans by administration of ddI and hydroxycarbamide
WO1995027485A1 (fr) * 1994-04-08 1995-10-19 The Procter & Gamble Company Methodes d'utilisation de chelates contenant du fer pour diminuer les atteintes dues aux radicaux libres chez les mammiferes
WO1997021683A1 (fr) * 1995-12-13 1997-06-19 Abbott Laboratories Composes inhibiteurs de proteases retrovirales
US5905068A (en) * 1996-09-24 1999-05-18 Abbott Laboratories Retroviral protease inhibiting compounds
US6114312A (en) * 1997-03-07 2000-09-05 Research Institute For Genetic And Human Therapy (R.I.G.H.T.) Method of inhibiting human immunodeficiency virus by combined use of hydroxyurea, a nucleoside analog, and a protease inhibitor
NL1009226C2 (nl) * 1998-05-20 1999-11-24 Faculteit Geneeskunde Universi Toepassing van een nucleïnezuur-bindend chemotherapeutisch agens, een farmaceutisch preparaat en een geneesmiddelcombinatie.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015329A1 (fr) * 1991-02-28 1992-09-17 The United States Of America, Represented By The Secretary, United States Department Of Commerce Procedes et compositions pharmaceutiques servant a inhiber la protease du virus de l'immunodeficience humaine
WO1992016200A1 (fr) * 1991-03-20 1992-10-01 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Utilisation de derives d'acide hydroxamique pour l'inhibition de la replication virale

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GAO W-Y ET AL: "ANTI-HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 ACTIVITY OF HYDROXYUREA INCOMBINATION WITH 2',3'-DIDEOXYNUCLEOSIDES", MOLECULAR PHARMACOLOGY, BALTIMORE, MD, US, vol. 46, no. 4, 1 October 1994 (1994-10-01), pages 767 - 772, XP000573476, ISSN: 0026-895X *
GEORGIOU NIKI A ET AL: "Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin.", JOURNAL OF INFECTIOUS DISEASES, vol. 181, no. 2, February 2000 (2000-02-01), pages 484 - 490, XP001027530, ISSN: 0022-1899 *
MALLEY S D ET AL: "SYNERGISTIC ANTI-HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 EFFECT OF HYDROXAMATE COMPOUNDS WITH 2',3'-DIDEOXYINOSINE IN INFECTED RESTING HUMAN LYMPHOCYTES", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 91, 1 November 1994 (1994-11-01), pages 11017 - 11021, XP000572692, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
DE60016044D1 (de) 2004-12-23
AU6483100A (en) 2001-03-13
WO2001012168A2 (fr) 2001-02-22
EP1257261A2 (fr) 2002-11-20
ATE282430T1 (de) 2004-12-15
EP1257261B1 (fr) 2004-11-17
NL1012825A1 (nl) 2001-02-14
NL1012825C2 (nl) 2001-02-23

Similar Documents

Publication Publication Date Title
IL215891A (en) Hepatitis C Serine Protease Inhibitors, Pharmaceutical Compounds Containing Them, and Their Use in Preparing Drugs to Treat Hepatitis C Infections
MY128458A (en) Antiviral azaindole derivatives
WO2002062290A3 (fr) Agents antiviraux constitues de 2-methylbenzimidazole substitue heterocyclique
IL139002A0 (en) Compositions for the treatment of hiv and other viral infections
MX9603909A (es) Derivados de sulfonamida como inhibidores de proteasa aspartilo.
WO2001085700A3 (fr) Inhibiteurs de la replication du vih
IL143512A (en) Azabicycloalkanes, pharmaceuticals including them and their use in the manufacture of drugs for the prevention or treatment of infection by the immunodeficiency virus
MY137777A (en) Inhibitors of aspartyl protease
WO2003053344A3 (fr) 2-methyl-benzimidazole substitues en tant qu'agents antiviraux du virus respiratoire syncytial
WO2001010456A3 (fr) Peptides bloquant les infections virales et procedes d'utilisation correspondants
GB0011203D0 (en) Chemical compounds
NZ306027A (en) Heterocyclecarbonyl amino acid hydroxyethylamin sulfonamide derivatives, preparation and use as retroviral protease inhibitors
DE60024419D1 (en) Aspartyl-protease-inhibitoren
IS6956A (is) Sítrat salt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9-pentaen og lyfjafræðilegar samsetningar af því
ATE299709T1 (de) Anti-virale zusammensetzung enthaltend ein palmaria palmata extrakt
WO2002040016A8 (fr) Association d'inhibiteurs de calpaïne et de piegeurs des formes reactives de l'oxygene
WO2002085358A3 (fr) Agents antiviraux et methodes de traitement d'infections virales
WO2001012168A3 (fr) Produit pharmaceutique utilise ans le traitement d'infections virales, notamment des infections dues au virus de l'immunodeficience humaine (vih)
DK1053012T3 (da) Farmaceutiske sammensætninger omfattende PEG-asparaginase til behandling af HIV-infektioner
WO2001008672A3 (fr) Composes glucamine destines au traitement d'infections dues au virus de l'hepatite
WO2002000613A3 (fr) Inhibiteurs d'infections par le virus de l'hepatite b (vhb)
MXPA04004061A (es) Derivados de quinolina y piridina antiretrovirales.
WO2001070216A3 (fr) Composes possedant une activite anti vih
HUP0402149A3 (en) Water-soluble phenylpyridazine derivatives, their use and pharmaceutical compositions containing the same
ZA200108398B (en) Anti-HIV-1 vaccine comprising all or part of the HIV-1 Tat protein.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000952070

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10049579

Country of ref document: US

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000952070

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 2000952070

Country of ref document: EP